Foley, Ronan
Kuruvilla, John
Funding for this research was provided by:
Novartis Pharma AG
Article History
Received: 19 October 2023
Accepted: 5 March 2024
First Online: 25 April 2024
Declarations
:
: Ronan Foley: Honoraria: Janssen, Bristol-Meyers Squibb, Novartis Canada; Scientific Advisory Boards: Novartis, Roche Canada. John Kuruvilla: Honoraria: Abbvie, Amgen, AstraZeneca, BMS, Beigene, Genmab Gilead, Incyte, Janssen, Karyopharm, Merck, Novartis, Pfizer, Roche, Seattle Genetics; Research support: Canadian Cancer Society Research Institute (CCSRI), Canadian Institutes of Heath Research (CIHR), Leukemia and Lymphoma Society Canada, Princess Margaret Cancer Foundation, AstraZeneca, Kite, Merck, Novartis; Consultant: Abbvie, BMS, Gilead/Kite, Merck, Roche, Seattle Genetics; Scientific Advisory Board: Lymphoma Canada (Chair); Data Safety Monitoring Board: Karyopharm.
: This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.